{
"id":"mk19_b_rm_q046",
"number":46,
"bookId":"rm",
"correctAnswer":"C",
"title":"Question 46",
"stimulus":[
{
"type":"p",
"hlId":"b0f96b",
"children":[
"A 28-year-old man is seen in follow-up for management of a multisystem febrile illness. Up until 6 weeks ago he was in good health. He takes no medications."
]
},
{
"type":"p",
"hlId":"1e269b",
"children":[
"On physical examination, temperature is 38.2 °C (100.8 °F), and blood pressure is 158/84 mm Hg. Bilateral 2+ ankle edema and bilateral tenderness and swelling of the metacarpophalangeal joints and wrists are observed. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8ebba5",
"class":"cell text l",
"children":[
"8.9 g/dL (89 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2989c0",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Leukocyte count",
"children":[
"Leukocyte count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"321a4d",
"class":"cell text l",
"children":[
"3800/μL (3.8 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e7710b",
"class":"cell text l",
"children":[
"90,000/μL (90 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"61f3aa",
"class":"cell text l",
"children":[
"C3 complement"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"28d0ed",
"class":"cell text l",
"children":[
"Low"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"323d2d",
"class":"cell text l",
"children":[
"C4 complement"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"28d0ed",
"class":"cell text l",
"children":[
"Low"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"51e313",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 μmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"131f5a",
"class":"cell text l",
"children":[
"Anti–double-stranded DNA antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b534b1",
"class":"cell text l",
"children":[
"Antinuclear antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d43bb8",
"class":"cell text l",
"children":[
"1:1280 (speckled pattern)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fb202e",
"class":"cell text l",
"children":[
"2+ blood; 3+ protein; dysmorphic erythrocytes; no casts"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3c82f4",
"class":"cell text l",
"children":[
"350 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"387a1a",
"children":[
"Kidney biopsy results are pending."
]
},
{
"type":"p",
"hlId":"92b486",
"children":[
"Prednisone is initiated."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Azathioprine"
}
},
{
"letter":"B",
"text":{
"__html":"Hydroxychloroquine"
}
},
{
"letter":"C",
"text":{
"__html":"Hydroxychloroquine and mycophenolate mofetil"
}
},
{
"letter":"D",
"text":{
"__html":"No additional therapy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"f40817",
"children":[
"For systemic lupus erythematosus that is organ-threatening, combination immunosuppressive therapy is indicated to control disease."
]
},
{
"type":"keypoint",
"hlId":"dc63e3",
"children":[
"For most patients with newly diagnosed lupus nephritis, induction with glucocorticoids and mycophenolate mofetil is the preferred immunosuppressive treatment."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"6b126e",
"children":[
"The most appropriate treatment is prednisone plus hydroxychloroquine and mycophenolate mofetil (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). This patient has new-onset systemic lupus erythematosus (SLE) with nephritis. Lupus nephritis can present with minimal laboratory abnormalities (non-nephrotic proteinuria, hematuria), frank nephritis (hypertension, lower extremity edema, active urine sediment, and elevated serum creatinine level), and/or nephrosis (nephrotic-range proteinuria, dependent edema, and thrombosis). Anti–double-stranded DNA antibody titers are a marker for risk, and complement consumption is a common phenomenon during active kidney disease. Untreated active disease may progress to kidney failure. He has few other symptoms of SLE, but laboratory findings and clinical presentation strongly suggest this diagnosis. Although kidney biopsy is indicated to determine histologic subtype and chronicity, treatment should not be delayed. High-dose or “pulse” glucocorticoids are indicated for new or recurrent active nephritis and should be followed by a glucocorticoid taper. Hydroxychloroquine is indicated in almost all patients with newly diagnosed SLE. In addition, for moderate or severe disease that is organ-threatening, additional immunosuppressive therapy is indicated to control disease and to allow for tapering of glucocorticoid therapy. For most patients with new nephritis, induction with mycophenolate mofetil is the preferred agent. Intravenous cyclophosphamide can also be used if patients have severe disease or are intolerant to mycophenolate."
]
},
{
"type":"p",
"hlId":"e99b77",
"children":[
"Prednisone plus azathioprine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") could be used as maintenance therapy, typically along with hydroxychloroquine, but azathioprine is not first-line therapy for new-onset lupus nephritis."
]
},
{
"type":"p",
"hlId":"6041bf",
"children":[
"Prednisone plus hydroxychloroquine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is appropriate initial therapy for mild SLE. However, in a patient with organ-threatening disease, such as lupus nephritis, combination immunosuppressant therapy that includes mycophenolate mofetil or cyclophosphamide is needed to control the disease."
]
},
{
"type":"p",
"hlId":"ecb537",
"children":[
"Prednisone alone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") will help control immediate symptoms, but without additional immunosuppressive agents, return of disease activity is likely as the prednisone dosage is tapered. Prolonged use of moderate- or high-dose glucocorticoids is associated with a variety of adverse outcomes and should be avoided."
]
}
],
"relatedSection":"mk19_b_rm_s7_4",
"objective":{
"__html":"Treat systemic lupus erythematosus with nephritis."
},
"references":[
[
"Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736-745. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30926722",
"target":"_blank"
},
"children":[
"PMID: 30926722"
]
}
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":6,
"B":18,
"C":57,
"D":19,
"E":0
},
"hlIds":[
"b0f96b",
"1e269b",
"a462a3",
"f9867c",
"8ebba5",
"2989c0",
"321a4d",
"fcac73",
"e7710b",
"61f3aa",
"28d0ed",
"323d2d",
"28d0ed",
"f461b2",
"51e313",
"131f5a",
"328929",
"b534b1",
"d43bb8",
"747c2a",
"fb202e",
"d17af8",
"3c82f4",
"387a1a",
"92b486",
"78ff87",
"f40817",
"dc63e3",
"6b126e",
"e99b77",
"6041bf",
"ecb537"
]
}